Sickle Cell Disease Patients dying from Opiates: Why no co-operation among doctors?

I am very concerned at what appears to be inadequate cooperation among medical practitioners who I had always assumed worked in harmony to improve the quality of patients' lives and save lives that can be saved.

If I have understood correctly, in the first few years of training, medical practitioners learn that opiates, notably morphine and heroin (Diamorphine) have an effect on the cerebellum and deprive the system of oxygen. It is therefore advised that as there are numerous alternatives available, they should absolutely not be used as a pain killer unless a patient is terminally ill, very near to death and in excruciating pain which no other pain killer can relieve.

Do I understood that those physicians who continue to prescribe these drugs have forgotten what they have been taught or choose to ignore the fact even when reminded? What is happening to the life-saving dictum of the profession where some doctors are concerned?

In November 2008, I went to an emergency room at a clinic in Geneva , Switzerland where I live, with a blasting chest pain. My condition was soon further complicated by excruciating pain in my left hip.

My new lease on life is because medical practitioners did not contest my refusal of a morphine injection to relieve excruciating pain in my chest and hip. The physicians attending to me would have loved to relieve me of the pain with morphine but respected the knowledge, however little, and understanding I had of the way in which opiates affect the brain and therefore the entire system. They deprive the system of oxygen which is desperately vital in my condition, Sickle Cell Disease.

I had double pneumonia and pleurisy. The infection had provoked a sickle cell crisis. Before they had realised the extent of my illness, the fact that I was a sickle cell disease (SC) patient was enough for the physicians attending me NOT to insist on administering morphine. One of them said that my pain had reached the maximum the human body could endure.

Unfortunately, some physicians force patients to have morphine. Whether one is a sickle cell patient or not, opiates in my opinion, are not to be recommended.

I am allergic to aspirin and therefore must avoid no fewer than 34 prescription and over-the-counter medications, including Ketorolac (Toradol) which is very effective in relieving excruciating pain.

There are so many misconceptions about sickle cell disease that I took the book “The Sickle Cell Disease Patient” by F I D Konotey-Ahulu to the clinic and my daughter handed it to the physician attending to me. My three adult children are well informed about my health issues and therefore telephoned Professor Felix Konotey-Ahulu abroad for guidance. My physicians were very happy to consult with him by telephone. He confirmed that I was right to refuse the administration of morphine and together they co-operated in making me comfortable and well again.

I was fortunate enough not to need a blood transfusion (neither total nor partial).

It may help medical practitioners to know that over the 12-days that I was in the clinic in Geneva, medication I was given was Dafalgan, Valium, Tramal, Perfalgan, Rocephine, Klacid, Franxiperine, Nexium and Tavanic and Motilium lingual. I also had Oxygen, NaCl and Glucose. No Morphine or Diamorphine!

On leaving the clinic in Geneva , I went to a convalescence clinic. A physician at the convalescence clinic asked why I had refused morphine. When I explained why, a colleague of his pointed to the back of his head, reminding him of the effect opiates have on the brain.

I am privileged to interact with physicians for whom I have the highest respect, one reason being because they take due consideration of what I, their patient, say and they listen to my children as well. The physicians are humble enough to take hold of a receiver and cooperate with another physician abroad in saving a life. They admit to me that they have been very happy to deepen their knowledge and would be pleased to learn more.

Had I been given the morphine or any other opiate, because of my double pneumonia with sickle cell disease, I would not be writing today, pleading with physicians to have compassion on patients who sometimes suffer very uncomfortable psychological problems (however temporary) as a result of having been given opiates and those who die as a result of having been given opiates.

The physicians who seem not to understand should try putting themselves in the position of families plunged into unbearable grief because of carelessness – a loved one was given opiates unnecessarily.

In spite of myself I begin to wonder whether Professor Felix Konotey- Ahulu's very practical and uncomplicated life-saving advice is being ignored by some medical practitioners because of his African origins. I believe his advice is based on what every medical practitioner learns at medical school.

Mawunu Chapman Nyaho
Geneva

Competing interests: None declared

Source : http://www.bmj.com/cgi/eletters/339/sep01_1/b3536#220670

UK drug related deaths are still rising: So where is NICE?

http://www.bmj.com/cgi/eletters/339/sep01_1/b3536#219836

Susan Mayor, 5 September, has done well to draw attention to 2 reports that reveal “the numbers of people dying because of poisoning from legal and illegal drugs are still increasing” [1] The first report said “Almost a third of the deaths where specific drugs were mentioned on the death certificate were related to heroin or morphine” [1, 2] The second report from St George’s University of London showed a 2.7% rise in the number of drug related deaths confirmed by inquest. Here too “Heroin and morphine accounted for most of these deaths” [3]. And these were the very drugs that the NCEPOD Report [4] found had produced deaths in sickle cell disease patients from overdose, and about which I continued to protest [5- 8].

HOW LONG WILL THIS CONTINUE FOR?

How long this situation is destined to continue is not clear. Writing to the Prime Minister and Health Ministers as I did, produced a response from Downing Street [6], but other ministers did not even bother to acknowledge my letters of concern. The United States of America has banned Diamorphine (Heroin) from all clinical practice [9], and that great country does not even have a National Institute of Health and Clinical Excellence (NICE). I would dearly want to know what percentage of the members of NICE are practicing Clinicians. Do they not know that Diamorphine suppresses respiration thus producing more in vivo sickling in sickle cell crisis [10, 11, 12]? Never mind how many UK Professors of Haematology approve of the practice, but do the Clinicians on NICE not know that it is this “legal” Diamorphine that (as Susan Mayor writes) is pushing up “the numbers of people dying because of poisoning from legal and illegal drugs” [1]?

IS MY PROTEST JUSTIFIED OR NOT?

But why do I continue protesting like this? ANSWER: First of all, I did not train in the bush somewhere in Africa. I was trained in London University’s Westminster Hospital School of Medicine by Physicians and Surgeons of King George VI and Queen Elisabeth II. My teachers taught me never to give Diamorphine or morphine to someone who could not breathe and whose red cells were bound to sickle further and clog up vital organs [13]. Secondly, I was second born of my parents’ 11 children 3 of whom had sickle cell disease, allowing me to know much about the disease before I went to university [14]. Thirdly, I was once in charge of the largest sickle cell disease clinic in the world, seeing personally hundreds of patients in sickle cell crisis [15, 16], salvaging many to grow up to use their brilliant non-sickling genes to achieve great things later in life, an experience which led me to begin writing about the sickle cell disease patient more than 44 years ago [17].

MY ADVICE TO NATIONAL INSTITUTE OF HEALTH AND CLINICAL EXCELLENCE

In the light of the above I make no apologies to take it upon myself to advise NICE to stop standing on the sidelines, and add to their many pronouncements one that forbids the “legal” use of Heroin (Diamorphine) for sickle cell disease patients. This, at least, was one thing NICE could learn from the USA [9].

GENETIC COUNSELLING AND VOLUNTARY FAMILY SIZE LIMITATION

The real answer for now, and the future, as I have been saying for decades is Genetic Counselling and Family Planning [18, 19] warning my fellow Africans that if they did not check themselves for a beta-globin gene variant (an ACHE gene) they might suddenly find themselves with a child born with an ACHEACHE phenotype (ACHE from father and ACHE from mother), like Sickle Cell Disease, and “the genetic burden on the National Health Service will go up and up” [20]. If born in the UK, the child could never escape Diamorphine treatment in sickle cell crisis. Was that really a prospect my country men and women would cherish?

Felix I D Konotey-Ahulu MD(Lond) FRCP DTMH Dr Kwegyir Aggrey Distinguished Professor of Human Genetics, University of Cape Coast, Ghana and Consultant Physician Genetic Counsellor in Sickle & Other Haemoglobinopathies, 10 Harley Street London W1G 9PF.

felix@konotey-ahulu.com

1 Mayor Susan. UK drug related deaths are still rising say two reports. http://www.bmj.com/cgi/content/full/339/sep01_1/b3536 BMJ 2009; 339: b3536

2 Deaths related to drug poisoning www.statistics.gov.uk/pdfdir/dgdths0809.pdf August 2009.

3 The St George’s Annual Report August 2009 www.sgul.ac.uk/about-st-georges/divisions/faculty-of-medicine-and- biomedical-sciences/mental-health/icdp/our-work-programmes/nationa/- programme-on-substance-abuse-deaths

4 NCEPOD (National Confidential Enquiry into Patient Outcome and Death). SICKLE: A Sickle Crisis? (2008) [Sebastian Lucas (Clinical Co- ordinator), David Mason (Clinical Co-ordinator), M. Mason (Chief Executive), D Weyman (Research), Tom Treasurer (Chairman)] info@ncepod.org

5 Konotey-Ahulu FID. Poor care for sickle cell disease patients: This wake up call is overdue BMJ Rapid Response May 28 2008 BMJ 2008; 336: 1152 http://www.bmj.com/cgi/eletters/336/7654/1152a#196224 to Susan Mayor “Enquiry shows poor care for patients with sickle cell disease” on National Confidential Enquiry into Patient Outcome and Death (NCEPOD) REPORT “SICKLE: A Sickle Crisis? (2008) info@ncepod.org

6 Konotey-Ahulu FID. Current “hit and miss” care provision for sickle cell disease patients in the UK. http://www.bmj.com/cgi/eletters/337/jul11_2/a771#199135 BMJ Rapid Response 22 July 2008

7 Konotey-Ahulu FID. Management of sickle cell disease versus management of the sickle cell disease patient. http://www.bmj.com/cgi/elettrs/337/sep08_1/a1397#202088 BMJ Rapid Response 17 September 2008

8 Konotey-Ahulu FID. Inquest into diamorphine deaths: Does NCEPOD sickle patients report warrant a similar inquest? BMJ Rapid Response March 7 2009 http://www.bmj.com/cgi/eletters/338/mar03_3/b903#210208

9 Ballas SK. Sickle Cell Pain. IASP Press. Seattle 1998.

10 . Konotey-Ahulu, FID. Morphine for painful crises in sickle cell disease. BMJ 1991, 302(6792): 1604. (June 29 1991) (Comment on Professor Chamberlain's recommendation of morphine in pregnancy in sickle cell disease – BMJ 1991; 302: 1327-30.) doi:10.1136/bmj.302.6792.1604-c http://www.bmj.com/cgi/reprint/302/6792/1604-c.pdf PMID: 1855060 PubMed- indexed for MEDLINE

11 Konotey-Ahulu FID. Opiates for sickle-cell crisis? Lancet 1998; 351(9113): 1438. May 9. PMID: 9593444 PubMed-indexed for MEDLINE

12 Konotey-Ahulu FID. Opiates for sickle-cell crisis. Lancet 1998; 352(9128): 651-652. Aug 22. PMID:9746049 PubMed-indexed to MEDLINE

13 Konotey-Ahulu FID. Opiates for pain in dying patients and in those with sickle cell disease. 11 October 2007 BMJ Rapid Response http://www.bmj.com/cgi/eletters/335/7622/685#177986

14 Konotey-Ahulu FID. Sickle Cell Disease in successive Ghanaian generations for three centuries (Manya Krobo Tribe) In The Human Genome Diversity Project: Cogitations of An African Native. Politics and the Life Sciences (PLS) 1999, Vol 18: No 2, pp 317-322. http://www.konotey- ahulu.com/images.generation.jpg

15 Konotey-Ahulu FID. The Sickle-cell Diseases: Clinical manifestations including the Sickle Crisis. Arch Inten Med 1974; 133(4): 611-619. http://archinte.ama.assn.org/cgi/reprint/133/4/611-pdf or http://archinte.ama.assn.org/cgi/content/abstract/133/4/611 [PMID: 4818434 PubMed – indexed for MEDLINE]

16 Konotey-Ahulu FID. The sickle cell disease patient: natural history from a clinico-epidemiological study of the first 1550 patients of Korle Bu Hospital Sickle Cell Clinic. Watford Tetteh-A’Domeno Company 1996 & The Macmillan Press Ltd, London 1991/1992.

17 Konotey-Ahulu FID. Publications annually from 1965 to 2009 http://www.konotey-ahulu.com/publications_annual.htm

18 Konotey-Ahulu FID. Sickle Cell Disease: The Case for Family Planning. Accra. ASTAB Books, Ltd 1973; 32 pages.

19 Ringelhann B, Konotey-Ahulu FID. Hemoglobinopathies and thalassemias in Mediterranean areas and in West Africa: Historical and other perspectives 1910 to 1997 – A Century Review. Atti dell’Accademia dell Science di Ferrara ( Milan) 1998; 74: 267-307.

20 Konotey-Ahulu FID. Need for ethnic experts to tackle genetic public health. http://www.thelancet.com/journals/lancet/article/PIIS0140- 6736(07)61771-1/fultext Lancet 2007; 370: 1836 [doi:10.1016/50140- 6736(07)61771-1]

Competing interests: None declared.

Sickle Cell Disease Patients dying from Opiates: Why no co-operation among doctors? Mawunu Chapman Nyaho

http://www.bmj.com/cgi/eletters/339/sep01_1/b3536#220670 British Medical Journal 21 September 2009

WARNINGS FROM A QUARTER OF A CENTURY AGO

WARNINGS FROM A QUARTER OF A CENTURY AGO

Ethnic minorities and sickle cell disease

British Medical Journal 20 April 1985  Volume 290, page 1214

 
SIR,-Dr John Black's article (30 March, p 984) is most helpful. Many family doctors are quite familiar with much of what he has so lucidly stated. The reason why many children (and adults) with sickle cell disease continue to die “before their time” in the UK and elsewhere is failure to appreciate certain facts relating to presentation, a failure of anticipation, and what I usually call a combination of circumstances.

First, presentation. Epistaxis, priapism, enuresis, numbness of the lower lip, sudden aphasia, hemiplegia, blood in the urine, deep jaundice, large tummy, nails white as a sheet, loud precordial murmurs, bruit de diable at the root of the neck, unexplained fever, cough with tachypnoea, fatigability, swollen hands may each and severally be the first indication that the child has sickle cell disease.' Alternatively, a child's condition may have nothing to do with sickle cell disease but may later be worsened by it-for example, within seven days lobar pneumonia can become pneumonia plus infarction plus pulmonary abscess.' Presentations may also differ from those described in the textbooks. (1) Teenagers of 12, 13, 14, or 15 years with SS disease may have spleens which, far from vanishing, are enlarged. (2) The child with genuine SS disease (parents AS, AS) with haemoglobin of 12-3 g/dl should not be treated as having sickle cell trait, because the potential for devastating in vivo sickling is there. (3) Extreme fatigability with “nails as white as a sheet” during an attack of measles indicates an aplastic crisis from the measles virus. Haemoglobin drops to 2-5 g/dl within 48 hours. As little as 100-150 ml of packed cells for a 5 year old child and not more than one unit for a 15 year old given over eight hours is lifesaving, even when the haemoglobin was less than 3 g/dl to start with.

Secondly, clinicians should anticipate disasters in patients with sickle cell disease. For example, if perioperative fluid therapy is not planned for a child about to undergo surgery the child will end up with a stroke. Anaesthetists are now more careful than ever so their success is virtually 100″,,, but fluid management before, during, and after operation often leaves a lot to be desired. The clinician should also be aware that the patient who has been admitted and discharged twice within the past week has come in again to die unless the whole management is overhauled.

Thirdly, there are many dangerous combinations of circumstances that may lead to disaster for the unwary. (1) Personnel: the houseman or GP is away for the weekend; the locum has little clue about what is happening and goes by the packed cell volume or haemoglobin concentration rather than the patient's condition; the casualty department may refuse to admit the patient, quibbling over whether the patient should go under a physician or a haematologist. (2) Clinical: abdominal pain might be due to sickle cell crisis,2 3 or the crisis could also have been precipitated by acute appendicitis.' (3) Genetic: hardly any west African with sickle cell anaemia is without one or more of the other hereditary erythrocytopathies: 86'U/ have concomitant lac or 2ac thalassaemia, and, although this is supposed to ameliorate the SS phenotype, 2OO, of the men and 16″(, of the women also have glucose-6- phosphate dehydrogenase (G6PD) deficiency.4 Contrary to what is claimed from the USA, G6PD deficiency on top of sickle cell disease is an added liability4 (Luzzato L, paper at International Symposium on Sickle Cell Anaemia, Abidjan, Ivory Coast, 1975). Workers in the UK should always identify which of their patients have G6PD deficiency, because several antimicrobial agents and analgesics which are given to help may in fact harm the patient.

FELIX KONOTEY-AHULU
London WIN IAA

1 Konotey-Ahulu FID. The sickle cell diseases. Clinical manifestations including the “sickle crisis.” Arch Intern Med 1974;133:611-19.
2 Hendrickse RG. Sickle cell anaemia in Nigerian children. Cent AfrJa Med 1960;6:45-57.
3 Valman HB. ABC of I to 7. London: British Medical journal, 1982:21.
4 Acquaye CTA, Gbedemah KA, Konotey-Ahulu FID. Glucose-6 phosphate dehydrogenase deficiency in sickle cell disease patients in Accra. Ghana Med 7 1977;16:15-8.

Current “hit and miss” care provision for sickle cell disease patients in the UK

Current “hit and miss” care provision for sickle cell disease patients in the UK

Following her article [1] on NCEPOD [2] Susan Mayor has, again, produced a succinct summary [3] of the recent publication of ‘Standards’ on the care of patients with sickle cell disease (scd) in the UK [4], written by a multidisciplinary working group chaired by Consultant Haematologist Dr Ade Olujohungbe. The public launch of the publication was on 9 July in the House of Commons where the Archbishop of York, Dr John Sentamu, said: “These Standards are another step in providing consistent care” [3].

HIT AND MISS CARE PROVISION

Hitherto, consistent care has not been UK’s strong point. The description by the ‘Standards’ Group’s chairman, Dr Olujohungbe who, in my opinion, has proved to be the most experienced Clinical Haematologist in the UK on the scd patient since Hammersmith Hospital’s Professor Lucio Luzzatto with whom Olujohungbe was closely associated, underlines what Graham Serjeant [5] and I have bemoaned for years. Olujohungbe said “The care provision for sickle cell disease is currently hit and miss, depending on the attitudes and experience of health professionals” [3]. This sad diagnosis by the leading UK haematologist on the scd patient was precisely why “NCEPOD found that many patients died of complications caused by excessive doses of opiods” [1, 2].

RESPONSE OF TEN DOWNING STREET

During the week when UK media (radio, television, & newspapers) were full of news that the Prime Minister was inviting personal phone calls and contacts on people’s concerns I took the opportunity to write to The Right Honorable Mr. Gordon Brown drawing his attention not only to the publication of the NCEPOD Report [2], but also to the international responses that were beginning to pour in [6]. The reply I got, dated 25 June 2008, from Ten Downing Street was encouraging: “Dear Dr Konotey-Ahulu – The Prime Minister has asked me to thank you for your recent letter and enclosures. Mr. Brown has asked that your letter be forwarded to the Department of Health so that they may reply to you on his behalf. (Signed) MR R SMITH”.

RESPONSE OF THE DEPARTMENT OF HEALTH

I looked forward eagerly to answers to the 3 questions I posed in my correspondence, namely (i) With respect to scd patients dying with overdose of opiods (heroin & morphine) in their blood “What kind of supervision led to this?” [6a] (ii) Why should West Indians and West Africans who did without morphine in their countries be put on morphine pumps when they were admitted to UK hospitals? [6a] (iii) To those UK haematologists who say “unbearable pain is unbearable pain, which must be treated with the most potent analgesic drugs known” I posed this third question, how many of them would prescribe diamorphine (heroin) monthly for their teenage daughters whose dysmenorrhoea was simply unbearable? [6a]. The Department of Health wrote back to me Ref; TO00000325139 dated 16 July 2008. Signed by “Shelley Wilson, Customer Service Centre”. All the questions were totally ignored. Would the National Institute of Clinical Excellence (NICE) now provide specific answers to these my 3 questions?

OUR GENETIC FUTURE

Africans, African-Caribbeans, and African Americans must wake up and realize that their genetic future depends on themselves, and not on any Department of Health. We must reduce the genetic disease burden, starting now, otherwise their children will continue to be subjected to “hit and miss” health care provision, ending up on heroin and morphine pumps. “Unless we Africans are involved in genetic counseling” and voluntary family size limitation (GCVFSL), I said not long ago “the genetic burden on the National Health Service will go up and up” [7]. What is more to the point, unless we take this very seriously our children and grand children will suffer greatly from scd [ACHEACHE syndrome], for “one in three West Africans in the UK has a beta-globin variant gene (ie NORMACHE) whose unsuspecting owner needs to be identified and helped with genetic counseling and family size limitation” [7]. Those who do not quite believe the enormity of the NCEPOD Report [2] should, please, start by taking a good look at how the rest of the world regards the “hit and miss” approach to the present care of sickle cell disease patients in the United Kingdom [6a-6j].

Felix I D Konotey-Ahulu MD(Lond) FRCP(Lond) DTMH(L’pool) – Kwegyir
Aggrey Distinguished Professor of Human Genetics, University of Cape Coast, Ghana and Consultant Physician Genetic Counsellor in Haemoglobinopathies, London W1G 9PF.

felix@konotey-ahulu.com

1 Mayor Susan. Enquiry shows poor care for patients with sickle cell disease. BMJ 2008; 336: 1152

2 NCEPOD (National Confidential Enquiry into Patient Outcome and Death) Sickle: A Sickle Crisis? (2008) [Sebastian Lucas (Clinical Co- ordinator), David Mason (Clinical Co-ordinator), M Mason (Chief Executive), D Weyman (Researcher), Tom Treasurer (Chairman)] info@ncepod.org

3 Mayor Susan. Group publishes standards for adult sickle cell disease to reduce number of unexplained deaths. BMJ 2008;337:a771

4 Sickle Cell Society (London) The Standards for the Clinical Care of Adults with Sickle Cell Disease in the UK. http://www.sicklecellsociety.org

5 Serjeant GR. The case for dedicated sickle cell centres. BMJ 2007; 334: 477 (3 March)

6a http://www.bmj.com/cgi/eletters/336/7654/1152-a#196224 [Felix I D Konotey-Ahulu 29 May 2008] Poor care for sickle cell disease patients: This wake up call is overdue

6b http://www.bmj.com/cgi/eletters/336/7654/1152-a#196359 [Kwabena Frimpong-Boateng 30 May 2008] Re: Poor care for sickle cell disease patients: This wake up call is overdue

6c http://www.bmj.com/cgi/eletters/336/7654/1152-a#196514 [Marianne Janosi 3 June 2008] “Poor care for patients with sickle cell disease” BMJ 24 May 2008 Volume 336.

6d http://www.bmj.com/cgi/eletters/336/7654/1152-a#196520 [Cecilia Shoetan 3 June 2008] I lost my Sickle Cell disease adult daughter minutes after being given Diamorphine intravenously when she could not breathe.

6e http://www.bmj.com/cgi/eletters/336/7654/1152-a#196631 [Frank Edwin 5 June 2008] Re: Poor care for sickle cell disease patients: This wake up call is overdue

6f http://www.bmj.com/cgi/eletters/336/7654/1152-a#196848 [Ivy Ekem 9 June 2008] Care for sickle cell patients

6g http://www.bmj.com/cgi/eletters/336/7654/1152-a#197301 [Mawunu Chapman Nyaho 17 June 2008] Poor care for the sickle cell disease patient: “Pain won't kill him, but Morphine could”.

6h http://www.bmj.com/cgi/eletters/336/7654/1152-a#197350 [Emmanuel Jeurry Blankson 18 June 2008] Sickle Cell Disease is managed, NOT treated.

6i http://www.bmj.com/cgi/eletters/336/7654/1152-a#197377 [Yolande M Agble 18 June 2008] Re: Poor care for sickle cell disease patients: This wake up call is overdue.

6j http://www.bmj.com/cgi/eletters/336/7654/1152-a#198669 [Akosua M Dankwa 11 July 2008] Sickle Cell patients deserve to live.

7 Konotey-Ahulu FID. Need for ethnic experts to tackle genetic public health. Lancet 2007; 370: 1826 (December 1)

Competing interests: I come from a sickle cell disease (scd) family, my parents were traits (NORMACHE), and I am actively involved in genetic counselling to reduce the burden of sickle cell disease (ACHEACHE) in future generations.

NCEPOD REPORT Reveals Sickle Cell Disease Patients in UK Hospitals Dying from Overdose of Morphine and Heroin (Diamorphine)

Sickle: A Sickle Crisis? (2008) info@ncepod.org

The National Confidential Enquiry into Patient Outcome and Death (NCEPOD)
published a report in May 2008 which showed that within the 2 years January
1 2005 to December 31 2006 “Nine out of the 19 patients with sickle cell
disease who had pain on admission and who then died had been given
excessiove doses of opiods”.

The International response to this revelation was huge – see
http://www.bmj.com/cgi/eletters/336/7654/1152-a#196224 and the subsequent 9
other comments.

Later, on 9 July 2008 in the House of Commons, another report was published
called “The Standards for The Clinical Care of Adults with Sickle Cell
Disease in the UK”. The Chairman of the Group that produced the report
described the present care of patients in the UK as a “hit and miss affair
depending on the attitudes and experience of health professionals”. Dr
Konotey-Ahulu's reaction to this in the British Medical Journal on line is
reproduced in full below 
http://www.bmj.com/gi/eletters/337/jul11_2/a771

Using Aerobic Oxygen

FURTHER ADVICE FROM ONE PATIENT TO ANOTHER PATIENT 
 
From Mawunu Chapman Nyaho (Europe) to Judi Hamilton (USA)
If I remmeber rightly, the little bottle of Aerobic Oxygen will last up to two months if you take about 20 drops three times daily.
 
I am grateful for your question because I forgot a very important point about pain killers. 
 
My brother “ended up” having a sickle cell crisis in late spring last year (2007).  Too much traveling by air, long working hours and enjoying wine or some other alcohol as an aperitif or with his evening meal were among things that led to the crisis.
 
He was given morphine to alleviate the excruciating pain.  As Professor Konotey-Ahulu put it when they spoke over the phone while my brother was in a hospital in Maine, “morphine will keep you in hospital”. (The School of Medicine in Ghana teaches doctors that morphine should be used only when a terminally ill patient is in great pain.).  Fortunately, the medical staff in Maine was willing to learn.  As soon as they were told that morphine was supressing the oxygen supply to his body (the crisis meant he already was suffering from lack of oygen), on Prof's advice, he was given shots of “Ketorolac”.  Within 48 hours my brother had been discharged from hospital.
 
Some doctors in hospitals in Europe are very stubborn and patietns and their families have to be very, very firm in refusing the use of morphine to alleviate pain.  Last summer, a father flew in from Canada and shared his daugher's hospital room for a week, until she was discharged, so that treatment that was further aggravating her condition would be stopped.  She had been given morphine and a full blood transfusion instead of a partial blood transfsion, so her blood became even thicker and normal oxygen supply to her body and brain was furher obstructed.
 
Please do read the Professor's blog and website regularly and, please do contact me, if necessary, for patient-to-patient exchanges.
 
There is nothing like walking into a doctor's office with tags on the essential pages of his book on The Sickle Cell Patient.
 
Rule 001 = live healthily, for living a healthy life is living without sickle cell crises.  Dr. Konotey-Ahulu asked about your job – that also falls into the “living healthily” category because if it is tiring and stressful you will need to do something about that.
 
A few more rules:
 
1.  Never allow morphine or any other opiate to be administered as a pain killer when in crisis.
 
2.  Inform yourself about partial blood transfusion.
 
3.  Know what your hemoglobin level is and never accept a blood transfusion that will raise it far above what your body is used to living relatively comfortably with.
 
4.  Avoid alcohol – make water your favorite drink.
 
I hope you have had your spleen checked.  Please do so as soon as possible.
 
With best wishes,
Mawunu

Patient-Achievers helping other patients with Advice

Dear Ms. Hamilton,
 
My apologies for not writing sooner.  I have not checked my e-mails in several days.  Below are a few points which come to mind immediately.  I shall be 60 in June.
 
As long as you feel unwell and have pain in your spleen or any other part of your body, I would avoid flying until your health problems are dealt with.  There is nothing like preventing a sickle cell crisis as a crisis is a miserable and unbelievably painful experience.
 
Drink two to three liters of water each day, avoid alcohol, do not eat heavy meals (prefeably four or five lighter meals a day), and do not have your last meal too late at night, keep your body weight down,  stay well rested, never exhaust yourself, do gentle exercise, walk.  Always dress warmly; even in hot weather, carry a light shawl around with you to protect you from sudden exposrue to cool draughts and air conditioning.
 
Your eyes need to be checked regualrly (i.e. approximately every six months) to make sure that you do not have any bleeding into the retina.  Unfortunately, this is a problem we 'SC' patients suffer from.  If blood vessels in your eyes rupture during a trip, you will most porbably not be able to fly home for medical care so it is extremely important that you should be in good health before flying.
 
I have found it extremely helpful to own a copy of “The Sickle Cell Disease Patient” by Dr Konotey-Ahulu, and I encourage doctors to have a copy on their bookshelves.  I also refer them to his website www.konotey-ahulu.com  We need to know our bodies and about our ailment so we can educate doctors as only too few know about it.   
 
I have learned from Dr. Konotey-Ahulu that there is a big difference between managing a patient and treating a disease. 
 
You can help any open-minded, receptive general practitioner who does not know much about sickele cell disease to manage you correctly.
 
Please ask Dr. Konotey-Ahulu what blood tests you should have.  My spleen has disappeared – if I remmeber rightly, it was overworked fighting infections.  Every three years or so I have a “pneumovax” shot and, at the beginning of winter, take a course of medication to make my immune system react quickly whenever I have an upper respiratory tract infection. 
 
A few drops of Aerobic Oxygen (stabilised oxygen) in a glass of water about three times a day is very helpful.  It is not sold in the US but can be ordred from Canada.  As I do not have the address within reach at the moment, I shall send it to you tomorrow.
 
All that I have learned about managing my problems with sickle cell disease has been thanks to Dr. Konotey-Ahulu.  My using Aerobic Oxygen is also thanks to him.
 
China and Australia will be well within your reach if you are in good health. 
 
Please spend a couple of years looking after your health then plan your trips with the necessary days of rest well below an altitude of 2000m.  The correct  and constant air pressure on board an aircraft is also important, particularly on long-haul flights.
 
I live in Geneva, Switzerland.  A small group of us is reaching out to other sicke cell patients in Geneva and forming a suport group as there are misconceptions and errors in treatment that are repeated.  We patinets need to know our bodies and be firm with doctors.  In the long run, they respect us for our knowledge and many of them are grateful to us for helping them improve our health.
 
If you know of any other sicke cell patints in Fort Lauderdale, you may wish to form a support group.
 
With best wishes,
Mawunu 

felix Konotey-Ahulu <admin@sicklecell.md> wrote:

Dear Judith
 
Thanks for writing. I'm off somewhere at the moment so I cannot respond in detail to your letter. 
 
Where are you? What do you do?
 
I'm copying your letter to a super lady who can help you. Her name is Mawunu Chapman Nyaho.
 
Meanwhile, go to my website www.konotey-ahulu.com
 
On the Home Page you will find on the right hand side 'PUBLICATIONS'. Click on it. That brings you to a page with dates from 1965. Scroll down the years to the Year 2001. Read all 4 articles listed in that year before getting back to me.
 
Felix Konotey-Ahulu

G6PD Deficiency in Ghanaians: How to recognise it

G6PD Deficiency in Ghanaians: How to recognise it  

In their instructive seminar Professors Capellini and Fiorelli put Africa first in the list of areas with the “highest frequencies of G6PD deficiency” (Jan 5, p 64) [1], so what are the Ghanaian associations?

(i) “Dorkita, I’m passing coca cola urine”. Mist alba, septrin, fansidar, chloramphenicol, APC, are the greatest offenders [2].

(ii) Typhoid disease [3 4]

(iii) lobar pneumonia with jaundice [2 4]

(iv) Renal failure [5](v) No enzyme-at-all in 5% G-6-P-D deficient males [6]

(vi) Greater delay in recovery from coma [7]

(vii) Greater representation in Cirrhosis of the liver [7]

(viii) Greater proportion of diabetics [7]

(ix) Sickle cell disease patients fare worse [8 9 10]

(x) Female homozygotes (X-X-) have more severe disease than hemizygotes (X-Y), making me wonder “how that can be reconciled with the Lyon hypothesis of inactivation of one X chromosome” [10, page 105]

(xi) Periodic intravascular haemolysis from interaction between “alpha thalassaemia type 1 equivalent to African homozygous alpha thalassaemia type 2, with G-6PD Total deficiency” [11]. Exercise acts as a trigger. The combination per se does not appear to account for the hyperbilirubinaemia in babies [All cases of ‘march haemoglobinuria’ must be screened for both alpha thalassaemia and G-6PD deficiency].

(xii) The enzyme is found in liver, brain, kidney, adrenals, skin, pancreas, nerve and muscle, hence the extra-erythrocytic manifestations of G6PD deficiency. Bedu-Addo’s description of chloroquine induced bilateral ptosis [12] could have been in one with no enzyme.

(xiii) Hepatomegaly with quick progression to cirrhosis [7]. (xiv) Viral Hepatitis is commoner in G6PD deficient patients, and characterised by intrahepatic cholestasis [13]. (xv) Terminology of A-minus (attributed to Africans) and B-minus (Mediterranean)is meaningless, as in A-minus Ghanaians “absence of enzyme in new red cells” produces cases “similar to the Mediterranean type of total deficiency” [6]

(xvi) There is an inexplicable north-south divide of incidence: 11% of males are deficient in the north [14] while 23% have G6PD deficiency in the south [15].

(xvii) Protection against malaria has not been proved in Ghana for hemizygotes and female homozygotes [7]. Indeed, blackwater fever is often related to G6PDdeficiency

(xviii) “Sabolaa  kε Emanbii yi” is a truism in my Krobo tribe: “Onions and M&B disagree” [16]. In the Colonial days some who took sulphonamides (‘M&B’) for infections fell gravely ill on eating onions. Dipropyl disulphide in onions “alters G6PD in the metabolic chain within the erythrocytes, which causes denaturing and precipitation of haemoglobin” [17].

(xix) Genetic Counselling goes beyond haemoglobinopathy to erythrocytopathy. A G6PD deficient sickle cell trait mother (AS) has two healthy daughters with her sickle cell trait (AS) husband, and they seek advice for a third pregnancy hoping to get a boy. She is told that although neither daughter has inherited her deficiency, and both avoided sickle cell anaemia (SS), her next child could be SS with G6PD deficiency (severe if a boy) [18]

(xx) Voluntary family size limitation (VFSL) [19] is the advice I give hemizygotes who (in Africa) have a high male procreative superiority index (MPSI) [20] in that males have more children than females, with consequent greater donation of abnormal genes to the next generation.

I declare that I have no conflict of interest Felix I D Konotey-Ahulu 

felix@konotey-ahulu.com

10 Harley Street, London W1G 9PF, UK

1     Capellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet 2008; 371: 64-74.

2     Owusu SK. Glucose-6-phosphate dehydrogenase (G-6PD) deficiency in the causation of disease in Ghana. Ghana  Med J 1974; 13: 168-170.

3        Owusu SK, Foli AK, Konotey-Ahulu FID, Janosi M. Frequency of Glucose-6-phosphate dehydrogenase deficiency in typhoid fever in Ghana. Lancet 1972; 1: 320.

4    Adu D, Anim-Addo Y, Foli AK, Yeboah ED, Quartey JKM. Acute renal failure and typhoid fever. Ghana  Medical Journal 1975; 14: 172-174.

5     Owusu SK, Addy JH, Foli AK, Janosi M, Konotey-Ahulu FID, Larbi EB. Acute reversible renal failure associated with glucose-6-phosphate dehydrogenase deficiency. Lancet 1972; 1: 1255-1257

6     Owusu SK. Absence of glucose-6-phosphate dehydrogenase in red cells of an African. BMJ  1972; 4: 25-26

7   Owusu SK. Clinical manifestations of glucose-6-phosphate dehydrogenase (G-6PD) deficiency in Ghana. Ghana Med J 1978; 17: 235-39.

8   Konotey-Ahulu FID. Glucose-6-phosphate dehydrogenase deficiency and sickle cell anaemia. New Eng J Med 1972: 287: 887-888.

9   Acquaye CTA, Gbedemah KA, Konotey-Ahulu FID. Glucose-6-pogosphate dehydrogenase deficiency incidence in sickle cell disease patients in Accra. Ghana Med J 1977; 16: 4-7

10      Konotey-Ahulu FID. The sickle cell disease patient: natural history from a clinico-epidemiological study  of 1550 patients of Korle Bu Hospital Sickle Cell Clinic. London: Macmillan 1992; Watford: Tetteh- A’Domeno Co 1996.

11   Konotey-Ahulu FID. Alpha thalassaemia nomenclature and abnormal haemoglobins. Lancet 1984; 1: 1024-1025

12   Bedu-Addo G. Chloroquine induced bilateral ptosis. Trans Roy Soc Trop Med Hyg 2006; 100: 696-697.

13      Morrow RH, Smetana HF, Sai FT, Edgecomb JH. Unusual features of viral hepatitis in Accra, Ghana. Ann Intern Med 1968; 68: 1250-1264.

14   Ringelhann B, Dodu SRA, Konotey-Ahulu FID, Lehmann H. A survey for haemoglobin variants, thalassaemia and Glucose-6-phosphate ehydrogenase deficiency in northern Ghana. Ghana Med J 1968; 7: 120-124.

15      Owusu SK, Opare-Mante A. Electrophoretic characterization of glucose-6-phosphate dehydrogenase (G6PD) enzyme in Ghana.  Ghana Medical Journal 1972; 11: 304.

16   Konotey-Ahulu FID. Probing anecdotes in traditional African therapeutics. African Journal of Health  Sciences 1194; 1: 53-56.

17      Fenwick G, Hanley AB. The genus Allium – Part 3 Section X Medicinal Effects. CRC Critical Reviews in Food Science and Nutrition 1985; 23: 1-73.

18      Konotey-Ahulu FID. Missing the wood for one genetic tree? In, The First International Symposium on the Role of Recombinant DNA in Genetics. Proceedings, Chanai, Crete – Greece, May 13 -16, 1985. Eds Loukopoulos D, Teplitz R. Athens, P Paschalidis 1986, pages 105-116.

19      Konotey-Ahulu FID.  The male procreative superiority index (MPSI): its relevance to genetical counselling in Africa. In: Eds, Oliver Mayo, Carolyn Leach. Fifty Years of Human Genetics. A Festschrift and liber amicorum to celebrate the life and work of George Robert Fraser. South Australia,                 Wakefield Press, August 2007 pages 48-50.

20    Konotey-Ahulu FID. Need for ethnic experts to tackle genetic public health. Lancet 2007; 370: 1826-27.

Ethnic minorities and sickle cell disease

Ethnic minorities and sickle cell disease

SIR,-Dr John Black's article (30 March,p 984) is most helpful.
Many family doctors are quite familiar with much of what he has so
lucidly stated. The reason why many children (and adults) with sickle cell disease continue to die “before their time” in the UK and elsewhere is failure to appreciate certain facts relating to presentation, a failure of anticipation, and what I usually call a combination of circumstances.

Firstly, presentation. Epistaxis, priapism, enuresis, numbness of the lower lip, sudden aphasia, hemiplegia, blood in the urine, deep jaundice, large tummy, nails white as a sheet, loud precordial murmurs, bruit de diable at the root of the neck, unexplained fever, cough with tachypnoea, fatigability, swollen hands may each and severally be the first indication that the child has sickle cell disease.'

Alternatively, a child's condition may have nothing to do with sickle cell disease but may later be worsened by it-for example, within seven days lobar pneumonia can become pneumonia plus infarction plus pulmonary abscess.' Presentations may also differ from those described in the textbooks.

(1) Teenagers of 12, 13, 14, or 15 years with SS disease may have spleens which, far from vanishing, are enlarged.
(2) The child with genuine SS disease (parents AS, AS) with haemoglobin of 12-3 g/dl should not be treated as having sickle cell trait, because the potential for devastating in vivo sickling is there.

(3) Extreme fatigability with “nails as white as a sheet” during an attack of measles indicates an aplastic crisis from the measles virus.

Haemoglobin drops to 2-5 g/dl within 48 hours. As little as 100-150 ml of packed cells for a 5 year old child and not more than one unit for a 15 year old given over eight hours is lifesaving, even when the haemoglobin was less than 3 g/dl to start with.

Secondly, clinicians should anticipate disasters in patients with sickle cell disease. For example, if perioperative fluid therapy is not planned for a child about to undergo surgery the child will end up with a stroke. Anaesthetists are now more careful than ever so their success is virtually 100″,,, but fluid management before, during, and after operation often leaves a lot to be desired. The clinician should also be aware that the patient who has been admitted and discharged twice within the past week has come in again to die unless the whole management is overhauled.

Thirdly, there are many dangerous combinations of circumstances that may lead to disaster for the unwary.

(1) Personnel: the houseman or GP is away for the weekend; the locum has little clue about what is happening, and goes by the packed cell volume or haemoglobin concentration rather than the patient's condition; the casualty department may refuse to admit the patient, quibbling over whether the patient should go under a physician or a haematologist.

(2) Clinical: abdominal pain might be due to sickle cell crisis,2 3 or the crisis could also have been precipitated by acute appendicitis.'

(3) Genetic: hardly any west African with sickle cell anaemia is without one or more of the other hereditary erythrocytopathies: 86'U/ have concomitant lac or 2ac thalassaemia, and, although this is supposed to ameliorate the SS phenotype, 2OO, of the men and 16″(, of the women also have glucose-6-phosphate dehydrogenase (G6PD) deficiency.4 Contrary to what is claimed from the USA,G6PD deficiency on top of sickle cell disease is an added liability4 (Luzzato L, paper at International Symposium on Sickle Cell Anaemia, Abidjan, Ivory Coast, 1975).

Workers in the UK should always identify which of their patients have G6PD deficiency, because several antimicrobial agents and analgesics which are given to help may in fact harm the patient.

FELIX KONOTEY-AHULU London WIN IAA

1 Konotey-Ahulu FID. The sickle cell diseases. Clinical manifestations including the “sickle crisis.” Arch Intern Med 1974;133:611-19.

2 Hendrickse RG. Sickle cell anaemia in Nigerian children. Cent AfrJa Med 1960;6:45-57.

3 Valman HB. ABC of I to 7. London: British Medical journal, 1982:21.

4 Acquaye CTA, Gbedemah KA, Konotey-Ahulu FID. Glucose-6 phosphate dehydrogenase deficiency in sickle cell disease patients in Accra. Ghana Med 7

1977;16:15-8.

Source : British Medical Journal 1985 (20 April), Volume 290, page 1214.